MA47015A - OLIGOMERIC CONJUGATES OF EXON JUMPING FOR MUSCLE DYSTROPHY - Google Patents

OLIGOMERIC CONJUGATES OF EXON JUMPING FOR MUSCLE DYSTROPHY

Info

Publication number
MA47015A
MA47015A MA047015A MA47015A MA47015A MA 47015 A MA47015 A MA 47015A MA 047015 A MA047015 A MA 047015A MA 47015 A MA47015 A MA 47015A MA 47015 A MA47015 A MA 47015A
Authority
MA
Morocco
Prior art keywords
muscle dystrophy
oligomeric conjugates
exon
jumping
exon jumping
Prior art date
Application number
MA047015A
Other languages
French (fr)
Other versions
MA47015B1 (en
Inventor
Gunnar J Hanson
Marco A Passini
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Priority claimed from PCT/US2017/066351 external-priority patent/WO2018118627A1/en
Publication of MA47015A publication Critical patent/MA47015A/en
Publication of MA47015B1 publication Critical patent/MA47015B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3233Morpholino-type ring
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3513Protein; Peptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/35Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA47015A 2016-12-19 2017-12-14 Exon skipping oligomer conjugates for muscular dystrophy MA47015B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662436199P 2016-12-19 2016-12-19
PCT/US2017/066351 WO2018118627A1 (en) 2016-12-19 2017-12-14 Exon skipping oligomer conjugates for muscular dystrophy

Publications (2)

Publication Number Publication Date
MA47015A true MA47015A (en) 2019-10-23
MA47015B1 MA47015B1 (en) 2022-11-30

Family

ID=66326249

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47015A MA47015B1 (en) 2016-12-19 2017-12-14 Exon skipping oligomer conjugates for muscular dystrophy

Country Status (2)

Country Link
AR (1) AR110537A1 (en)
MA (1) MA47015B1 (en)

Also Published As

Publication number Publication date
MA47015B1 (en) 2022-11-30
AR110537A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
MA55629A (en) ANTIBODY COMPOSITIONS FOR THE TREATMENT OF TUMORS
MA44486A (en) EARLY INTERVENTION METHODS TO PREVENT OR MITIGATE TOXICITY
MA46652A (en) POLYTHERAPY FOR C3 INHIBITION
MA44054A (en) BISPECIFIC ANTIBODY PLATFORM
MA46878A (en) BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS
MA52801A (en) OLIGOMERIC CONJUGATES TO EXON SKIP FOR MUSCLE DYSTROPHY
MA46048A (en) BEGINNER KIT FOR TITRATION OF BASIC INSULIN
MA50533A (en) IMIPRIDONES FOR GLIOMAS
FR3034840B3 (en) FLEXIBLE LIGHTING ASSEMBLY FOR CURVED VENTS
FR3018964B1 (en) INTERCONNECTION ELEMENT FOR CONNECTING STATOR COILS
FR3020758B1 (en) COMPOSITION FOR IMPROVING BUCO-DENTAL HYGIENE
FR3023015B1 (en) METHOD FOR FACILITATING THE APPROACH TO A PLATFORM
MA45845A (en) COMBINATION TREATMENT FOR HEMATOLOGICAL CANCERS
MA46898A (en) COMPOSITIONS FOR ORGAN CONSERVATION
FR3031502B1 (en) POINT SET FOR AN INSTRUMENT
FR3028523B1 (en) PROCESS FOR IMPROVING THE COKEFACTION RESISTANCE OF A LUBRICATING COMPOSITION
MA51822A (en) ALKANOIC ACID EXTRACTION
FR3031206B1 (en) INTERCONNECTION BOX FOR UTILITIES
FR3030253B1 (en) COMPOSITION FOR IMPROVING THE CELLULAR ASPECT OF THE SKIN
FR3033489B3 (en) GUIDE FOR THE POSITIONING OF ORTHODONTIC ATTACHES
MA47015A (en) OLIGOMERIC CONJUGATES OF EXON JUMPING FOR MUSCLE DYSTROPHY
MA51582A (en) OLIGOMERIC CONJUGATES OF EXON JUMPING FOR MUSCLE DYSTROPHY
MA51587A (en) OLIGOMERIC CONJUGATES OF EXON JUMPING FOR MUSCLE DYSTROPHY
FR3046235B1 (en) INTERCHANGEABLE SUPPORT FOR FASTENING A TURBOMACHINE
FR3040408B1 (en) MODULAR WORK STRUCTURE FOR STAIR CAGE